Alaric DeArment
Reporter

Latest From Alaric DeArment
Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.
Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
Evelo Forges Ahead In Psoriasis As Atopic Dermatitis Pathway Narrows
The company said the first three cohorts of its Phase II atopic dermatitis study failed, while another trial with a faster-release formulation of EDP1815 continues, along with a Phase III study in psoriasis.
CAR-Ts May Be Closer Competitors To Lilly’s Jaypirca Than Fellow BTK Inhibitors
The Loxo@Lilly drug got FDA accelerated approval in mantle cell lymphoma as the first non-covalent BTK inhibitor, enabling its use in post-BTKi disease.
J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
Ocuphire Eyes Phase III Path For APX3330 After Mixed Trial Results
The diabetic retinopathy candidate failed on its Phase II primary endpoint, but showed efficacy on a key secondary endpoint that the company hopes to use as the Phase III primary outcome measure.